STOCK TITAN

[SCHEDULE 13D/A] ProQR Therapeutics N.V. Amended Major Shareholder Report

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

ProQR Therapeutics N.V. received an amended Schedule 13D showing that a group of related Dutch investment entities led by Van Herk Investments B.V. beneficially owns 15,384,250 ordinary shares, representing 14.6% of the company’s ordinary shares outstanding as of September 30, 2025.

From October 3, 2025 to February 5, 2026, Van Herk Investments B.V. bought an additional 1,054,560 shares in open-market transactions for a total of $2,154,236.73, funded from its general working capital. The filing states the shares are held for investment, but the reporting persons may engage with ProQR’s management and board, discuss strategy and potential business combinations, propose changes to capitalization or board structure, or buy or sell more shares depending on market and company conditions.

Positive

  • None.

Negative

  • None.

Insights

Van Herk group now holds 14.6% of ProQR with potential activist-style engagement.

The amended Schedule 13D shows Van Herk Investments B.V. and affiliated Dutch entities collectively beneficially owning 15,384,250 ProQR ordinary shares, or 14.6% of shares outstanding as of September 30, 2025. Between October 3, 2025 and February 5, 2026, Van Herk Investments B.V. acquired 1,054,560 shares in open-market trades for an aggregate $2,154,236.73, using general working capital.

The purpose section describes a flexible investment approach. The group indicates it acquired the stake for investment in the ordinary course, yet expressly leaves open options such as communicating with management and the board, talking with other stockholders about the issuer, and discussing potential business combinations or dispositions. It also lists possible recommendations on capitalization, ownership structure, board composition, and financial or operational performance.

These disclosures mean the Van Herk group has positioned itself as a significant shareholder with latitude to act, but without committing to specific steps. Future company filings or ownership updates may clarify whether they increase or reduce their stake or pursue governance or strategic proposals after February 5, 2026.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of ProQR Therapeutics N.V. (the "Issuer") issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


SCHEDULE 13D


Van Herk Investments B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:02/06/2026
Van Herk Investments THI B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:02/06/2026
Van Herk Private Equity Investments B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:02/06/2026
Stichting Administratiekantoor Penulata
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:02/06/2026
Van Herk Management Services B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:02/06/2026
Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:02/06/2026
A. van Herk Holding B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:02/06/2026
Stichting Administratiekantoor Abchrys
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:02/06/2026
Adrianus van Herk
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:02/06/2026
Comments accompanying signature:
* Pursuant to a Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons.
Proqr Therapeuti

NASDAQ:PRQR

PRQR Rankings

PRQR Latest News

PRQR Latest SEC Filings

PRQR Stock Data

153.80M
86.28M
18.04%
51.67%
0.52%
Biotechnology
Healthcare
Link
Netherlands
Leiden